Breathe

Our medical research library holds 6 studies published in Breathe (2017–2025). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 6 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: European Respiratory Society
• Published: 2004 to the present, England
• Language: English
• ISSN: 1810-6838 (print), 2073-4735 (electronic)
• Its record in the NLM Catalog

2020s

• Asbestos and benign pleural diseases: a narrative review. L. Ferreiro, M.E. Toubes, N. Rodríguez-Núñez, et al. 2025;21(2):240236. Review PubMed · Publisher · Free full text

  Abstract

  The term "asbestos" is used to refer to a group of silicate minerals that often break down into fibres and whose inhalation over time can cause a number of diseases, especially pleuropulmonary diseases. While the most serious complications are malignant diseases, inhalation of these fibres can also cause benign pleural diseases such as round atelectasis, pleural plaques, diffuse pleural thickening and non-malignant asbestos pleural effusion. Although asbestos is banned in most developed countries (in the European Union, since 2002), it is still used in developing countries. Despite these restrictions, the prevalence of diseases due to inhalation remains high due to the long latency period between the onset of exposure and the onset of disease. In this paper we review benign pleural diseases induced by asbestos exposure, update the diagnostic criteria for these disorders, and describe the approaches suggested so far to differentiate them from malignant pleural diseases.

  Copyright ©ERS 2025.

• Malignant pleural mesothelioma associated with recurrent pneumothorax. L. Gumber, C.H. Lim, M.H. Naseer, et al. 2025;21(1):240226. Case report PubMed · Publisher · Free full text

  Abstract

  Secondary pneumothoraces can be the first presentation of pleural malignancies and may also complicate their course. They are often associated with prolonged air leaks, and cardiothoracic intervention can be required. https://bit.ly/3DEvPem.

  Copyright ©ERS 2025.

• Peri-procedural cardiac arrest at medical thoracoscopy in a patient with pleural mesothelioma causing resultant heart failure and an intractable pleural effusion. G. Hood, S. Lakey, E. Turnbull, et al. 2025;21(4):250175. Case report PubMed · Publisher · Free full text

  Abstract

  Tension hydrothoraces can cause significant morbidity and even mortality. The resultant heart failure caused the development of an intractable effusion and hyponatraemia which led to the patient's death. https://bit.ly/4m6jGjj.

  Copyright ©ERS 2025.

• Contemporary management of mesothelioma. M.D.J. Neilly, J. Pearson, A.W. Thu, et al. 2024;20(2):230175. Review PubMed · Publisher · Free full text

  Abstract

  Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are also rising in many countries despite utilisation bans. For many years, platinum--pemetrexed chemotherapy was the solitary licensed therapy, but first-line combination immune checkpoint blockade has recently demonstrated improved outcomes, with both regimes tested in predominantly late-stage cohorts. In the second-line setting, single-agent nivolumab has been shown to extend survival and is now available for routine use in some regions, while second-line chemotherapy has no proven role and opportunities for clinical trials should be maximised in relapsed disease. Surgery for "technically resectable" disease has been offered for decades in many expert centres, but the recent results from the phase III MARS2 trial have challenged this approach. There remains no robustly proven standard of care for early-stage PM. The clinical trial landscape for PM is complex and increasingly diverse, making further development of specialist PM multidisciplinary teams an important priority in all countries. The observation of improving outcomes in centres that have adopted this service model emphasises the importance of high-quality diagnostics and equitable access to therapies and trials. Novel therapies targeting a range of aberrations are being evaluated; however, a better understanding of the molecular drivers and their associated vulnerabilities is required to identify and prioritise treatment targets.

  Copyright ©ERS 2024.

• Malignant pleural disease. L.M. Piggott, C. Hayes, J. Greene, et al. 2023;19(4):230145. Review PubMed · Publisher · Free full text

  Abstract

  Malignant pleural disease represents a growing healthcare burden. Malignant pleural effusion affects approximately 1 million people globally per year, causes disabling breathlessness and indicates a shortened life expectancy. Timely diagnosis is imperative to relieve symptoms and optimise quality of life, and should give consideration to individual patient factors. This review aims to provide an overview of epidemiology, pathogenesis and suggested diagnostic pathways in malignant pleural disease, to outline management options for malignant pleural effusion and malignant pleural mesothelioma, highlighting the need for a holistic approach, and to discuss potential challenges including non-expandable lung and septated effusions.

  Copyright ©ERS 2024.

2010s

• Asbestos and the lung: highlights of a detrimental relationship. M. Iliopoulou, C. Bostantzoglou, R. Nenna, et al. 2017;13(3):235-237. PubMed · Publisher · Free full text

  Abstract

  Novel aspects of the pathogenesis of asbestos-related diseases are still coming to light http://ow.ly/EPDa30e8JqK.

Browse every journal in the library or the library by type of article, or return to medical research.